Clinical Study Data: Hand Efficacy

Voltaren targets pain at the site of inflammation

Clinically proven to reduce pain and stiffness for patients with hand OA

Hand OA Impacts Women 2x More Than Men

Women are nearly 2x as likely as men to develop hand OA

According to the Arthritis Foundation, women are nearly twice as likely as men to develop hand OA (47% versus 25%)¹. Despite there being no cure, the right treatment options can help manage their condition.

Study Summary: Voltaren delivers significant pain relief for patients with hand OA
Study objective & methodology

A multicenter, 8-week, randomized, double-blind, placebo-controlled study was conducted to assess the efficacy and safety of topical diclofenac sodium 1% gel (DSG) in patients with symptomatic hand OA aged ≥ 40 years. Eligible patients were randomized in a 1:1 ratio to receive diclofenac DSG or vehicle, four times daily for 8 weeks.

Results:

At Week 6, DSG was significantly superior to vehicle in all primary outcome measures including pain intensity, total AUSCAN, AUSCAN function, and AUSCAN stiffness.

Topical diclofenac sodium gel was generally well tolerated and effective in primary hand OA.

Improvements in the DSG group (16%–25%) were 47% to 125% greater than the vehicle group at Weeks 1 through 6, and 21% greater at Week 8.

Download our study summary to learn more about how Voltaren reduced pain and improved physical function for patients suffering from hand OA.

Download now